title: Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
abstract: Repeated injection of pegylated liposomes could elicit the disappearance of long-circulating characteristic, referred to as "accelerated blood clearance phenomenon." ABC phenomenon typically occurs when entrapped drugs are not cytotoxic, but recently it was reported that multiple doses of pegylated liposomal topotecan, a cytotoxic drug, could also induce the phenomenon in rats. To reveal whether the phenomenon could be induced in dogs and the effect of time interval between doses on the magnitude of ABC, pLT was repeatedly injected into beagle dogs with a time interval of 7, 21 and 28 days. The anti-PEG Ig M levels were detected using ELISA. It was found that ABC phenomenon could be induced in dogs by pLT. Inter-individual difference in anti-PEG antibody production could be observed, and antibody levels were directly correlated with the magnitude of ABC. Furthermore, time interval between doses had marked effect on the magnitude of ABC phenomenon. When the time interval was prolonged from 1 week to 4 weeks, ABC phenomenon could be eliminated. By comparing the pharmacokinetic profiles of lipid vesicles and entrapped topotecan, it was found that "empty pegylated vesicles" be formed in circulation, which might be responsible for the occurrence of ABC phenomenon.
authors: School of Pharmacy, Hebei Medical University, Shijiazhuang, PR China.
authors: ChunLei
authors: C
authors: Li
authors: Xi
authors: X
authors: Zhao
authors: YaJuan
authors: Y
authors: Wang
authors: HanYu
authors: H
authors: Yang
authors: HaiXia
authors: H
authors: Li
authors: Huan
authors: H
authors: Li
authors: Wei
authors: W
authors: Tian
authors: Jian
authors: J
authors: Yang
authors: JingXia
authors: J
authors: Cui
mesh_terms: D000818:Animals; D004285:Dogs; D004334:Drug Administration Schedule; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D004339:Drug Compounding; D007075:Immunoglobulin M / Q000097:blood; D007262:Infusions, Intravenous; D008081:Liposomes; D008657:Metabolic Clearance Rate; D010316:Particle Size; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D012995:Solubility; D013499:Surface Properties; D013997:Time Factors; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage* / Q000097:blood*; D019772:Topotecan / Q000008:administration & dosage* / Q000097:blood*
chemical_list: D004337:Drug Carriers; D007075:Immunoglobulin M; D008081:Liposomes; D059004:Topoisomerase I Inhibitors; D011092:Polyethylene Glycols; D019772:Topotecan